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SUMMARY 
Polyfunctional CD8+ effector T cells (Teff) can persist in large quantities in 
mice and humans with controlled, persistent intracellular infections; however, the 
cellular mechanisms that maintain ongoing effector responses are unclear. Here 
we describe a mouse model in which an immunodominant CD8+ T cell response 
exerts tight control over a persistent intracellular parasitic infection: a scenario 
that is reminiscent of anti-HIV T cell responses in rare individuals who control the 
infection.  We show that the continuous production of large numbers of short-
lived Teff cells is maintained via a proliferative, antigen-sensitive intermediate 
population (Tint) with a memory/effector hybrid phenotype. Our data highlight the 
importance of a Tint amplifying population to optimize memory/effector 
homeostasis during persistent infection. Targeting the Tint subset may serve as 
effective strategy for better T cell vaccines against chronic infections. 
 
 
 
 
 
 
 
 
 
 
  
INTRODUCTION 
CD8+ T cells provide protection against intracellular pathogens through a 
division of labor involving antigen-experienced effector and memory T cells.  This 
process has been extensively examined in models of acute infection, in which 
pathogen-specific naïve CD8+ T cells rapidly expand and differentiate in 
response to signals from antigen and other environmental cues (Arens and 
Schoenberger, 2010; Jameson and Masopust, 2009; Rohr et al., 2014). Upon 
pathogen clearance, short-lived effector T cells (Teff) die from apoptosis and a 
long-lived population of memory T cells (Tmem) remains (Joshi et al., 2007; Zehn 
et al., 2009). Long-lasting memory following acute infection is mediated by a 
stem cell-like population within the Tmem compartment that can self-renew or 
differentiate to generate new Teff upon secondary challenge (Gattinoni et al., 
2011; Graef et al., 2014; Luckey et al., 2006).  
While the generation of Tmem cells has been a major focus of vaccine 
strategies, emerging evidence highlights the important protective function of an 
on-going CD8+ Teff response (Masopust and Picker, 2012). For example, strong 
immune protection induced by a heterologous prime and boost strategy is due to 
a persistent Teff response (Jabbari and Harty, 2006; Masopust et al., 2006; Olson 
et al., 2013).  Likewise, a prolonged Teff response is associated with protection in 
a promising cytomegalovirus (CMV) vector-based vaccine for simian 
immunodeficiency virus (SIV) (Hansen et al., 2011; Hansen et al., 2009; Watkins 
et al., 2008). These long-lasting Teff are generally maintained by ongoing 
exposure to antigen (Mackay et al., 2012; Nelson et al., 2013), however in many 
  
settings, persistent antigen leads to T cell exhaustion.  Indeed, much of our 
knowledge regarding T cell responses to persistent infections comes from 
models in which pathogen control is incomplete and T cells become functionally 
impaired over time (Virgin et al., 2009; Wherry, 2011).  Therefore, the cellular 
mechanisms that maintain long-lasting effective control of persistent pathogens 
are not well understood. 
Mouse cytomegalovirus (MCMV) infection is an important experimental 
model for understanding ongoing CD8+ Teff responses.  Studies of MCMV 
infection in mice revealed continuous generation of Teff cells from an antigen-
experienced progenitor population with a memory-like phenotype (Snyder et al., 
2008) and a requirement for ongoing antigen presentation to maintain the CD8+ 
effector response (Snyder et al., 2011; Torti et al., 2011). One complicating 
feature of the MCMV infection model is the late expansion of certain CD8+ T cell 
VSHFLILFLWLHVDSKHQRPHQRQ WHUPHG ³PHPRU\ LQIODWLRQ´ (Karrer et al., 2003). An 
additional complexity is the dominant protective role of NK cells in the C57BL/6 
(B6) strain of mice (Vidal and Lanier, 2006).  As a result, this model has not 
allowed for dissection of the developmental pathway that leads to continuous 
CD8+ effector generation in vivo.  Hence, there is a pressing need for new 
mouse infection models to investigate the mechanism of CD8+ effector 
maintenance during controlled persistent infection. 
A key to maintaining effective CD8+ T cell control of persistent intracellular 
pathogens is the allelic form of the host major histocompatibility complex (MHC) 
locus.  For example, the ability to generate highly effective T cell responses to 
  
human immunodeficiency virus (HIV) is strongly linked to MHC-class I (MHC-I) 
polymorphisms that affect peptide binding (International et al., 2010; Kosmrlj et 
al., 2010). Moreover, HIV ³HOLWHFRQWUROOHUV´LQGLYLGXDOVZKRUHPDLQGLVHDVHIUHH
without anti-viral therapy, often harbor polyfunctional CD8+ T cells specific for 
viral peptides presented by protective allelic forms of MHC-I (Almeida et al., 
2007; Horton et al., 2006). Thus, an ideal experimental model for effective control 
of persistent infection may rely on particular combinations of host MHC-I and 
pathogen-derived antigenic peptides that can elicit unusually long lasting CD8+ T 
cell responses, along with a pathogen that has evolved to persist in the face of 
immune control. 
We considered that infection of a resistant mouse strain by the 
intracellular protozoan parasite, Toxoplasma gondii, might provide such an ideal 
experimental model. Toxoplasma parasites can induce a strong CD8+ T cell 
response, typically establish life-long persistence in their mammalian hosts, and 
often produce asymptomatic infections.  Moreover, mice harboring the MHC-I 
molecule Ld exhibit particularly effective control of the parasite, due to an 
immunodominant CD8+ T cell response directed against the parasite protein, 
GRA6 (Blanchard et al., 2008; Brown et al., 1995). In contrast, infected mice 
without the protective Ld MHC-I molecule develop a chronic progressive infection 
associated with dysfunctional T cell responses (Bhadra et al., 2011). 
Interestingly, both mouse MHC-I Ld, and certain human MHC-I alleles associated 
with elite HIV control, share key polymorphic amino acids in the peptide binding 
site, and exhibit limited peptide binding capacity (Kosmrlj et al., 2010; Narayanan 
  
and Kranz, 2013). Thus, parasite infection in resistant mice shares a number of 
features of HIV elite control, including an atypical MHC-I allele that confers strong 
protection, a robust ongoing CD8+ Teff response, and persistent but 
asymptomatic infection. 
In the current study, we examine the anti-T. gondii CD8+ T cell response 
in genetically resistant mice to gain insight into the maintenance of highly 
effective T cell responses.  We show that low-level persisting antigen 
presentation drives continuous production of polyfunctional Teff without a notable 
contraction phase.  Using a combination of the effector marker KLRG1, and the 
chemokine receptor CXCR3, we identify three subsets of antigen-experienced 
CD8+ T cells whose numbers are maintained over time by balanced proliferation, 
differentiation, and cell death.   In addition to a relatively quiescent, memory like 
population, and a terminally differentiated Teff population, we also identify a 
metabolically active intermediate population, which has a hybrid memory/effector 
phenotype, and is strongly dependent on persistent antigen for its survival, 
proliferation and Teff differentiation. Our results reveal that highly effective CD8 T 
cell control of a persistent pathogen is maintained by a division of labor in which 
a Tint subset allows for efficient and flexible generation of Teff in response to 
changing antigen levels, while a Tmem population provides for long-term 
maintenance of the response. 
 
 
RESULTS 
 
  
The CD8+ T cell response to T. gondii in genetically resistant mice exhibits 
immunodominance, and a long-lasting polyfunctional effector response. 
Strong immune protection against the persistent intracellular protozoan 
parasite Toxoplasma gondii in genetically resistant mice is linked to the MHC-I 
allele Ld and presentation of a single antigenic peptide derived from the parasite 
dense granule protein, GRA6 (Blanchard et al., 2008). We compared the anti-
GRA6:Ld response to subdominant CD8+ GRA4:Ld- and ROP5:Db-specific T cell 
responses (Frickel et al., 2008; Grover et al., 2014) using F1 (H-2bxd) mice orally 
infected with tissue cysts generated from the type II T. gondii strain, Prugniaud 
(Pru). The number of infected cells in both the draining mesenteric lymph nodes 
(MLN) and spleen peaked at 7 days after infection and then declined to 
undetectable levels by day 21. We detected a low but persistent level of T. gondii 
DNA in the brain beginning 11 days after oral infection (Figure 1A), reflecting the 
ability of T. gondii to establish chronic infection by encysting in the brain 
(Ferguson et al., 1989). In spite of parasite persistence, infected hosts did not 
show any sign of illness at >6 months post infection (data not shown), confirming 
the resistance of mice expressing the Ld allele of MHC-I (Brown et al., 1995). 
To compare multiple CD8+ T cell populations in the same animal, we used 
fluorochrome-labeled peptide-MHC-I (pMHC-I) tetramers to detect T. gondii-
specific T cells ex vivo by flow cytometry. At day 21 after infection, GRA6:Ld-
specific CD8+ T cells represented ~20% of total CD8+ T cells, and were 100-fold 
more abundant than the subdominant GRA4:Ld- and ROP5:Db-specific T cells 
(Figure 1B). At day 11, the subdominant T cells expanded only 40-200 fold 
  
relative to their numbers at day 3, whereas splenic GRA6:Ld-specific T cells 
expanded ~10,000 fold to ~5x105 cells/spleen during the same time period, and 
continued to expand to reach the peak of ~106 cells/spleen at 21 days post 
infection (Figure 1C). Anti-GRA6:Ld-specific T cells peaked at day 21 in the brain 
and persisted to at least day 200 after infection, while the subdominant T cells 
were 100-fold less numerous (Figure 1C). The majority of brain GRA6:Ld-specific 
T cells were not labeled by intravenous injection of CD45.1 antibody, indicating 
they resided in the brain parenchyma, and exhibited a phenotype consistent with 
tissue-resident memory T cells (Figure S1A and S1B) (Wakim et al., 2010). 
Intriguingly, the number of T. gondii-specific T cells in the spleen was maintained 
near peak levels throughout the chronic phase of infection in spite of the sharp 
decline in parasite load (Figure 1A and 1C).  Hence, the T. gondii-specific CD8+ 
T cell response in resistant mice is characterized by rapid expansion of a single T 
cell specificity, and maintenance of large parasite-specific T cell population 
without a contraction phase. 
While the loss of T cell effector function, termed T cell exhaustion, is 
observed in many chronic infections (Virgin et al., 2009), GRA6:Ld-specific T cells 
from chronically infected mice exhibited potent in vivo killing activity and 
produced high levels of IFNȖ and TNFĮ simultaneously upon brief ex vivo 
restimulation (Figure 1D and 1E). T cells specific for subdominant parasite 
antigens, in addition to their reduced numbers, produced lower levels of IFNȖ and 
the majority failed to co-express TNFĮ (Figure 1E). GRA6:Ld-specific T cells also 
maintained higher expression of the effector marker KLRG1, and lower 
  
expression of the memory marker CD62L compared to the subdominant T cell 
responses (Figure 1F). T. gondii-specific T cells also lacked expression of the T 
cell exhaustion marker PD-1 during the chronic phase of infection, expressing it 
only transiently during the expansion phase (Figure 1F). Thus, the CD8+ 
GRA6:Ld-specific T cell response is characterized by a large, polyfunctional 
effector population that persists throughout chronic infection. 
 
Persistent antigen presentation correlates with GRA6:Ld-specific T cell 
proliferation during the chronic phase of infection. 
The lack of a contraction phase and persistent effector function suggested 
that a low level of antigen presentation during the chronic phase of infection 
might drive the continuous generation of new Teff cells. To measure antigen 
presentation in vivo, we transferred naïve GRA6:Ld-specific transgenic T cells 
(TG6) (Figure S2) into previously infected mice and assessed their proliferation 3 
days after transfer (Figure 2A).  Substantial proliferation was observed when 
naïve TG6 T cells were transferred into mice that had been infected 140 days 
earlier with Pru strain parasites, but not in mice infected with a parasite strain that 
lacks the GRA6 epitope (Figure 2B). Thus, in spite of parasite clearance from 
secondary lymphoid organs (Figure 1A), GRA6 antigen presentation persisted 
late into chronic infection. 
We also observed that 5-10% of total GRA6:Ld-specific cells in chronically 
infected mice were in cell cycle, based on expression of the proliferation marker 
Ki67, and overnight in vivo incorporation of the DNA analog EdU (Figure 2C and 
  
2D). Interestingly, the decline of antigen presentation after initial infection 
correlated with the gradual reduction in the proportion of GRA6:Ld-specific T cells 
in cycle (Figure 2C).  Together, these data suggest that persistent GRA6 antigen 
presentation drives the proliferation of a subset of GRA6:Ld-specific T cells during 
chronic infection.  
 
GRA6:Ld-specific T cell immunodominance correlates with the 
predominance and persistence of a CXCR3+KLRG1+ population.   
Ongoing proliferation within the numerically stable GRA6:Ld-specific T cell 
population implies that the population size is maintained dynamically by 
continuous production of new cells balanced by cell loss. To investigate these 
population dynamics, we examined the composition of the dividing and non-
dividing GRA6:Ld-specific T cell populations in more detail. 
The GRA6:Ld-specific T cell response did not appear to be maintained by 
precursor population with a classic central memory phenotype (Sallusto et al., 
1999), since antigen experienced GRA6:Ld specific T cells were uniformly CCR7- 
CD62L- (Figure S3A).  In addition, while the combination of markers often used 
to distinguish effectors from memory precursors (KLRG1 and CD127)(Joshi et 
al., 2007) divided the population into three subsets, the proliferating population 
was equally distributed between these subsets (Figure S3B and S3C). In 
contrast, the combination of KLRG1 and CXCR3 revealed a KLRG1+CXCR3+ 
population that was highly enriched for proliferating cells (Figure S3B and S3C).  
  
We also noted that the antigen experienced T cell subsets defined by 
CXCR3 and KLRG1 differ in their proportions between dominant GRA6 and 
subdominant GRA4/ROP5 specificities (Figure 3A). In particular, the GRA6:Ld-
specific T cells consistently contained a higher proportion of CXCR3+KLRG1+ 
cells compared to the GRA4:Ld/ROP5:Db-specific T cells (Figure 3A and 3B). 
Moreover, the CXCR3+KLRG1+ subset of the GRA6:Ld-specific population 
persisted throughout infection, whereas the CXCR3+KLRG1+ subset in the 
GRA4:Ld/ROP5:Db-specific T cells exhibited a marked decline between days 10-
42 of infection and became barely detectable by day 60 after infection (Figure 3A 
and 3B). Thus, GRA6:Ld-specific T cell immunodominance correlates with the 
predominance and stability of the CXCR3+KLRG1+ population.   
Recent thymic emigrants (RTEs) were reported to contribute to the 
stability of the antigen-specific CD8+ T responses in some persistent infections 
(Snyder et al., 2008; Vezys et al., 2006). To examine the role of RTEs in 
maintaining the GRA6-specific T cell population, we transferred a small number 
of naïve TG6 T cells into congenic recipients before oral infection, and 
enumerated TG6 cells over the course of infection. All three CXCR3/KLRG1 
subsets in donor TG6 T cells demonstrated similar kinetics to the endogenous 
GRA6:Ld-specific T cells, highlighted by maintenance of the near-peak numbers 
and the lack of contraction (Figure 3C).  These data indicate that a stable GRA6-
Ld-specific T cell population can be maintained over time without contribution 
from recent thymic emigrants.  
 
  
The CXCR3+KLRG1+ subset has both memory and effector cell 
characteristics 
To better understand the relationship of the CXCR3/KLRG1 populations to 
previously defined memory and effector T cells, we performed additional flow 
cytometric analysis of GRA6:Ld-specific CD8+ T cells from chronically infected 
mice. As expected based on Ki67 staining (Figure 4A, Figure S2B and S2C), 
CXCR3+KLRG1+ cells incorporated the highest level of the thymidine analog 
EdU after an overnight labeling (Figure 4A), confirming that most proliferating 
cells are found within this subset.  CXCR3+KLRG1+ cells also had the highest 
levels of the nutrient update receptors, CD71 and CD98 (Figure 4A) implying that 
they are more metabolically active. CXCR3+KLRG1+ subset expressed relatively 
low levels of the anti-apoptotic molecule Bcl-2 (Figure 4B) and high levels of the 
effector marker Blimp-1, but also expressed a memory associated phenotype of 
CD122+, CD27hiCD43lo (Hikono et al., 2007), and Eomeshi (Banerjee et al., 2010) 
(Figure 4C). In vitro cytotoxicity assays on sorted CXCR3/KLRG1 populations 
(Figure S3D to S3E) demonstrated that the CXCR3-KLRG1+ subset harbored 
the strongest cytotoxicity, followed by the CXCR3+KLRG1+ subset, while the 
CXCR3+KLRG1- subset exhibited minimal killing capacity (Figure S3F). Thus, 
the CXCR3/KLRG1 gating strategy subdivided anti-T. gondii CD8+ T cells into 
three subsets of distinct functions and phenotypes, and identified a proliferative 
CXCR3+KLRG1+ subset with both memory and effector cell characteristics.  
 
 
  
Lineage relationship and antigen dependence of the CXCR3/KLRG1 
subsets. 
To explore the developmental relationship among the CXCR3/KLRG1 
subsets, we sorted GRA6:Ld-specific CXCR3/KLRG1 subsets from infected mice 
and followed their fates upon transfer into congenically marked infected 
recipients (Figure S4A). GRA6:Ld-specific CXCR3+KLRG1- and 
CXCR3+KLRG1+ cells proliferated and expanded 35 and 19 fold respectively 
between days 2 and 21 after transfer, whereas majority of the CXCR3-KLRG1+ 
cells did not proliferate, and their numbers declined with a half-life of 28 days 
(Figure 5A and 5B). Interestingly, CXCR3+KLRG1- cells gave rise to all three 
subsets after transfer, whereas CXCR3+KLRG1+ cells gave rise only to 
CXCR3+KLRG1+ and CXCR3-KLRG1+ cells, and finally, CXCR3-KLRG1+ cells 
maintained their phenotype (Figure 5B). Similar CXCR3/KLRG1 profiles were 
obtained upon transfer of CXCR3/KLRG1 subsets into T and B cell deficient (rag-
/-) mice during acute infection, although both donor CXCR3+ subsets underwent 
greater expansion compared to transfer into wild type recipients (Figure S4B). In 
summary, these experiments support the lineage relationship of CXCR3+KLRG1- 
Î CXCR3+KLRG1+ Î CXCR3-KLRG1+, and confirm that CXCR3-KLRG1+ 
cells are terminally differentiated.   
To examine the role of antigen in the differentiation and survival of the 
CXCR3/KLRG1 subsets, we transferred sorted populations into naïve recipients. 
Twenty-one days after transfer all donor CXCR3/KLRG1 subsets maintained 
their phenotypes, and the majority had not divided (Figure 5C). Based on the 
  
recovery of donor cells at day 2 and day 21 post transfer, CXCR3+KLRG1- cells 
showed the greatest survival with a half-live of 89 days, whereas 
CXCR3+KLRG1+ and CXCR3-KLRG1+ subsets displayed half-lives of 10 and 20 
days respectively (Figure 5D).  These relative half-lives are consistent with the 
expression of anti-apoptotic protein Bcl-2, which is lowest in the short-lived 
CXCR3+KLRG1+ population (Figure 4B).  These data suggest that antigen is 
required for differentiation and proliferation of both CXCR3 expressing subsets. 
Based on their developmental order, phenotype and functional properties, we 
hereafter refer to CXCR3+KLRG1- cells as Tmem, CXCR+KLRG1+ cells as Tint, 
and CXCR3-KLRG1+ cells as Teff.  
 
Persistent antigen presentation prevents T cell contraction by sustaining 
the amplifying Tint population. 
The results from cell transfer experiments and the strong antigen-
dependence of the Tint population imply that maintenance of this population by 
residual antigen is key to preventing T cell contraction following activation and 
expansion.  To further test this idea, we examined the GRA6:Ld specific response 
to irradiated parasites, which can invade host cells and trigger a CD8+ T cell 
response, but fail to establish chronic infection in vivo (Hiramoto et al., 2002). To 
allow for a similar infection in the acute phase, we used an intraperitoneal (i.p.) 
route of infection with either 106 irradiated parasites or 105 live parasites.  Initial 
levels of GRA6 antigen presentation and early T cell expansion were comparable 
after injection of either irradiated or live parasites (Figure 6A and 6B). However, 
  
while antigen levels remained high 42 days after infection of mice with live 
parasites, antigen levels in mice injected with irradiated parasites were markedly 
reduced by day 12 and undetectable at day 42 post-infection (Figure 6A).  
Transient antigen presentation in mice infected with irradiated parasites 
correlated with a 80% loss of total GRA6:Ld-specific T cells between day 12 and 
day 21 (Figure 6B) and a sharp reduction in the proportion of Ki67+ cells (Figure 
6C).  In contrast, mice infected i.p. with live parasites exhibited little or no 
contraction phase (Figure 6b), and ongoing proliferation within Tmem and Tint 
subsets (Figure 6C), similar to the results obtained from orally infected mice 
(Figure 3).  Interestingly, while all CXCR3/KLRG1 subsets declined during the 
contraction phase, the greatest reduction in cell number occurred in the Tint 
subset (Figure 6D and 6E).  These data are consistent with the relative half-lives 
of the 3 populations following transfer into naïve mice (Figure 5D), and confirm 
that the Tint subset is particularly dependent on persistent antigen for its survival 
and proliferation. 
We considered that a decline in presentation of the subdominant antigens 
could help to explain the loss of the Tint population amongst T cells responding to 
these antigens (Figure 3A and 3B).  To test this idea, we examined the in vivo 
kinetics of presentation of the subdominant antigen ROP5, by transferring naïve 
T cells from ROP5:Db-specific TCR transgenic mice (termed TR5 mice, Figure 
S5) into infected mice. Unlike the gradual reduction observed for the GRA6 
antigen (Figure 6F and Figure 2C), presentation of the ROP5 antigen dropped 
sharply between days 13 to 50, corresponding to the kinetics of loss of the 
  
tetramer+ Tint T cells (Figure 6F).  These data further support the importance of 
persistent antigen and the Tint population in maintaining an ongoing T cell 
response, and also help to explain the immunodominance of the GRA6:Ld-
specific T cell population. 
 
Mathematical modeling illustrates the role of the amplifying Tint subset in 
sustaining a robust Teff response. 
The ability of the Tmem, but not the Tint population, to replenish all 3 
subsets and survive in the absence of antigen implies that the Tmem population 
supports the long-term maintenance of the GRA6:Ld-specific effector response, 
while Tint cells provide short-term amplification of the response. Consistent with 
this notion, Tint in chronically infected mice exhibit a relatively high proliferation 
rate, whereas Tmem are relatively quiescent (Figure 4A). 
To further explore the roles of Tmem and Tint subsets in maintaining the Teff 
response, we considered two alternative models.  In one model, Tmem can divide 
to either produce another Tmem cell (self-renewal) or differentiate directly into a 
non-dividing Teff cell (Figure 7A).  A second model includes a Tint population that 
can divide to produce another Tint cell (amplification) or can differentiate into a 
non-dividing Teff (Figure 7B and Figure 5A, see also Experimental Procedures). 
In both models, we assumed that Teff disappear with a constant death rate of 
0.027 cells/day (i.e. 2.7% of total Teff die each day) based on the cell transfer 
experiments in Figure 4B.  
  
We first used model 1 to explore the range of Tmem self-renewal and 
differentiation rates that would allow for the observed overall rate of Teff 
production of 2.5x106 Teff from 105 Tmem at steady state (Figure 3B). By varying 
Tmem self-renewal and differentiation rates (O1 and [1, respectively), we found 
that the self-renewal rate O1 had to be greater than 0.3 cells/day to generate 
2.5x106 Teff at steady state (Figure 7C). This value is incompatible with the 
observed low rate of proliferation within the Tmem population (i.e. 6% of the Tmem 
population was labeled with EdU in every 14 hours, or 0.1 cells/day, see also 
Figure 4A).  Moreover, increasing the differentiation rate to approach the self-
renewal rate led to a sharp decline in the number of effectors, due to the 
depletion of the Tmem population (Figure 7C and data not shown).   
To evaluate the plausibility of model 2, we varied the Tint amplification and 
differentiation rates (O2 and [2, respectively) while leaving the remaining 
parameters set at control values estimated from available experimental data 
(Table S1A, see also Experimental Procedures), and calculated the number of 
Teff at steady state (Figure 7D).  We observed that an amplification rate (O2) of 
0.5 cells/day or greater would allow for the generation of 2.5x106 Teff at steady 
state (Figure 7D). This value is in line with observed rate of proliferation within 
the Tint population (i.e. 29% EdU-labeled cells in 14 hours, or 0.5 cells/day, see 
also Figure 4A).  Moreover, unlike model 1, in which increasing the differentiation 
rate led to a precipitous drop in Teff production (Figure 7C), increasing the 
differentiation rate [2 for model 2 led to a gradual decline in Teff numbers and 
never led to complete elimination of the response (Figure 7D). We also observed 
  
that the theoretical time course generated using model 2 and control parameters 
(Table S1A) correlated well with the experimental data derived from both the 
steady state cell number and cell transfer experiments (Figure 7E, Figure 3, and 
Figure 5A). These data suggest how the Tint population can allow for rapid high-
level production of Teff cells (Figure S6), and can modulate the rate of 
differentiation of Teff without depleting a key progenitor population needed to 
sustain the response over the long-term. 
 
DISCUSSION 
An ongoing T cell effector response is key to protective T-cell based 
vaccines, as well as natural resistance to persistent intracellular pathogens such 
as HIV (Masopust and Picker, 2012).  However, the mechanisms that maintain 
robust T cell effector responses are largely unknown, due in part to the lack of 
appropriate mouse infection models.  Here we show that persistent, 
asymptomatic T. gondii-infection in genetically resistant (H-2d) mice gives rise to 
a robust immunodominant CD8+ effector response that is maintained over time 
without a contraction phase, and without any signs of functional exhaustion. We 
investigated the cellular mechanisms that maintain this effector response, 
revealing a division of labor in which a relatively quiescent and long-lived 
memory population (Tmem) gives rise to terminally differentiated effector cells (Teff) 
via a proliferative, antigen-sensitive intermediate population (Tint). Our data 
provide novel insight into the cellular dynamics that maintain robust ongoing 
CD8+ T cell effector responses, and highlight the importance of an amplifying Tint 
  
population to generate adequate numbers of new Teff in response to changing 
pathogen levels, while preserving a long-lived Tmem population. 
Achieving a stable, asymptomatic standoff between an intracellular 
pathogen and an ongoing Teff response requires both a pathogen that is able to 
occupy a long-term niche in the host, and a T cell response with appropriate 
specificity to provide highly effective immune control.  With regard to the latter, it 
is intriguing to note that MHC-I variants associated with HIV elite control, and the 
MHC-I molecule Ld that presents the immunodominant parasite antigen GRA6, 
share structural features including atypical peptide binding properties 
(International et al., 2010; Kosmrlj et al., 2010; Narayanan and Kranz, 2013).  For 
the GRA6 antigen, a number of other factors contribute to efficient antigen 
presentation, including the secretion pattern of the antigenic protein within the 
invaded host cell, and the location of the epitope within the precursor protein 
(Feliu et al., 2013; Grover et al., 2014; Lopez et al., 2015). Thus, both features of 
a particular antigenic protein and presentation by an atypical MHC-I molecule 
may contribute to generating an unusually protective CD8+ T cell response.  
In addition to the protective pressure exerted by T cells, the ability of 
certain pathogens to adopt a relatively latent form in the host also contributes to 
the stable standoff between pathogen and host immune response. We showed 
that continued presence of the parasite, leading to persistent low-level antigen 
presentation, is required to prevent T cell contraction and maintain robust Teff 
responses.  T. gondii is able to achieve long-term persistence by converting to a 
relatively dormant, cyst-forming stage in the brain of its infected host (Montoya 
  
and Liesenfeld, 2004). Likewise the ability of E-herpesvirues, including 
cytomegalovirus (CMV), to adopt a latent form in mammalian host cells, likely 
provides a continuous source of antigen, which may explain the remarkable 
potency and longevity of Teff responses elicited by a CMV-based vaccine against 
SIV in non-human primates (Hansen et al., 2011; Hansen et al., 2009). 
Interestingly, heterologous prime-boost vaccination strategies can generate long 
lived effector responses without persistent infection (Jabbari and Harty, 2006; 
Masopust et al., 2006; Olson et al., 2013). However, there can be sustained 
antigen presentation after acute viral infection (Turner et al., 2007), in part due to 
formation of immune-complexes (Leon et al., 2014). 
A large body of literature using acute infection models has subdivided 
antigen-experienced CD8+ T cells into effector and memory populations based 
on cell surface markers including CCR7, CD62L, CD127 (IL7RD), and KLRG1 
(Joshi et al., 2007; Sallusto et al., 1999; Wherry et al., 2003).  Interestingly, the 
distinction between central memory (CCR7+CD62L+) and effector memory 
(CCR7-CD62L-) (Sallusto et al., 1999; Wherry et al., 2003) does not appear to be 
relevant in this infection model, since antigen experienced GRA6:Ld-specific 
CD8+ T cells were uniformly low for CCR7 and CD62L. This included the 
CXCR3+KLRG1- population that could give rise to all other subsets and was 
long-lived in the absence of antigen, and thus resembled a memory population.  
Moreover, CD127, which has been used in conjunction with the effector marker 
KLRG1 to distinguish memory precursor versus short-lived effectors (Joshi et al., 
2007), does not appear to be useful marker in this infection model.  Rather, 
  
transition from CXCR3+KLRG1+ Tint to CXCR3-KLRG1+ Teff phenotype 
correlated with the loss of proliferation and terminal differentiation of effector 
cells.  Interestingly, Yap and colleagues observed cycling T cells of 
CXCR3+KLRG1+ phenotype in an acute T. gondii vaccination model, and found 
that Teff terminal differentiation correlated with CXCR3 downregulation in an IL-12 
and IFNJ dependent manner (Kohlmeier et al., 2011; Kurachi et al., 2011; Shah 
et al., 2015). Together with our results, these findings suggest that the precise 
timing of TCR and cytokine/chemokine signals may be important for regulating T 
cell amplification and effector differentiation during infection by modulating the 
CXCR3+KLRG1+ Tint subset.  
Our modeling studies point to the role of Tint cells in maintaining an 
ongoing Teff response. Without the Tint population, Tmem cells would need to 
proliferate extensively to keep up with the demand for new Teff cell output.  
Moreover, if increasing antigen levels were to drive more rapid differentiation into 
Teff, this would lead to the depletion of the Tmem population and eventually the 
collapse of the T cell response.  Hence the presence of the Tint population allows 
for rapid production of new Teff, while maintaining a relatively quiescent Tmem 
population when antigen levels remain constant, and provides extra capacity for 
increasing Teff differentiation in response to increasing antigen levels.  
One interesting feature of the Tint population is high expression of the T-
box transcription factor Eomes.  Eomes, and the related transcription factor T-bet 
play partially redundant roles in CD8+ T cells, although Eomes also plays unique 
roles in the maintenance of memory and exhausted T cells (Banerjee et al., 
  
2010; Intlekofer et al., 2005; Paley et al., 2012). Interestingly, high Eomes 
expression is also associated with a proliferative subset of CD8+ T cells found 
some HIV-infected individuals, which correlates with effective viral control 
(Simonetta et al., 2014). Moreover, Eomes is expressed at high levels in 
intermediate neural progenitor cells, where it is required for the maintenance of 
the intermediate population and ongoing neurogenesis (Hodge et al., 2008; 
Hodge et al., 2012). Understanding the precise role of Eomes in maintaining 
robust CD8+ T cell effector responses during persistent infection is an important 
area for future investigation.  
In summary, we used a controlled persistent T. gondii infection model to 
delineate the cellular mechanism that sustains a long-term CD8+ Teff response. 
We identified a novel T cell intermediate subset that provides for efficient effector 
cell output, and is responsive to antigen levels. Approaches to manipulate the 
size of the Tint subset, perhaps via regulated release of antigen, may improve the 
efficacy of current vaccine regimens by sustaining robust Teff responses (Beura 
et al., 2014; Demento et al., 2012), while preserving a stable Tmem population.   
 
EXPERIMENTAL PROCEDURES 
 
Animals 
B6 (C57BL/6), B6 Rag2-/- (B6-Cg-Rag2tm1.1Cgn/J), B6.C (B6.C-H2d/bByJ), BALB/c, 
BALB/c Rag2-/- (C.B6(Cg)-Rag2tm1.1Cgn/J), CBA, CD45.1+ congenic B6 (B6.SJL-
Ptprca Pep3b/BoyJ), B6 Blimp1-YFP reporter (B6.Cg-Tg Prdm1-EYFP 1Mnz/J) 
were obtained from The Jackson Laboratory (Bar Harbor, ME) or The Charles 
River Laboratory (Wilmington, MA). In order to monitor multiple T. gondii 
epitopes, F1 mice (B6xB6.C or B6xBALB/c) expressing both the H-2b and H-2d 
MHC class I molecules were used for all experiments. For adoptive transfer 
experiments, only B6xB6.C F1 mice were used. This included the GRA6:Ld-
specific and the ROP5:Db-specific TCR transgenic (TG6 and TR5, respectively) 
mice, which were maintained on the B6 background and were then bred with 
B6.C mice to F1 background (H-2b/d). All animals were used or infected between 
  
six to ten week-old. For all infection and adoptive transfer experiments, sex- and 
age-matched genetically homogeneous mice were used, therefore no 
randomization was required. Mice bred in UC Berkeley animal facility and were 
used with the approval of the Animal Care and Use Committee of the University 
of California. 
 
Infection 
Mice were orally fed 70-80 cysts or injected intraperitoneally (i.p.) with 1×105 live 
tachyzoites from the type II Prugniuad-tomato-OVA strain (Pru)(Chtanova et al., 
2008). This strain harbors immunogenic T cell epitopes derived from the parasite 
proteins, GRA6 (Blanchard et al., 2008), GRA4 (Frickel et al., 2008), and ROP5 
(Grover et al., 2014), and is engineered to express red fluorescent protein (RFP), 
allowing for tracking infected cells by flow cytometry. In some experiments, mice 
were immunized i.p. with 1x106 irradiated Pru tachyzoites (14,000 rads). In other 
experiments, tachyzoites from type III CEP strain parasites were used for 
infection. CEP expresses an allelic version of GRA6 that lacks the T cell-
stimulatory epitope (Grover et al., 2014), and is used here as a negative control.  
Cysts were obtained from brains of CBA mice infected for 3±5 weeks i.p. with 
400 live Pru tachyzoites. Parasite loads in spleen and lymph nodes was analyzed 
by flow cytometry and parasite load in the brain was analyzed by semi-
quantitative PCR (Grover et al., 2014).  
 
Generation of the T. gondii GRA6:Ld -specific (TG6) and ROP5:Db-specific 
(TR5) TCR transgenic mice 
The TCR alpha and beta chain sequences of the GRA6:Ld-specific CTgEZ.4 T 
cell hybridoma (Blanchard et al., 2008) were determined according to Kraig et al 
(Kraig et al., 1996). The GRA6:Ld-specific and ROP5:Db-specific TCRs 
corresponded to TRAV6-7/DV9*01, TRAJ52*01. Then, both TCR chains were 
cloned and amplified from the genomic DNA of the CTgEZ.4 cell line by using 
forward primer specific for TRAV6-'9 ¶-
TCTCCCGGGGTCTAAAGATGAACTCTTCTCCAGG) and reverse primer for 
75$- ¶-TAAGCGGCCGCTGAGCGC AGTAAAGATT CTAGC); forward 
SULPHU VSHFLILF IRU 75%9 ¶-TCT CTCGAG 
TCTCAGAGATGTGGCAGTTTTGC) and reverse primer for TRBJ2- ¶-TAAG 
CCGCGG TCCTGGAAATGCTGGCACAAACC). Similarly, the ROP5:Db-specific 
TCR alpha and beta chains were cloned and amplified from the genomic DNA of 
the BTg45Z cell line (Grover et al., 2014) by using forward primer specific for 
75$9 ¶- TCT CCC GGG GGA AGA ATG ATG AAG ACA TCC CTT CAC 
AC) and reverse primer foU75$- ¶- TAA GCG GCC GCG TCT TGG TGA 
GTG AGC AAG ACA GAA G); forward primer specific for TRBV13- ¶- TCT 
CTC GAG TTCTGAG ATG GGC TCC AGA CTC TTC) and reverse primer for 
TRBJ2- ¶- TAAG CCG CGG CGC CCA CTG CAG CCC AAT CCC GCT 
GAG). 
 
In all cases, the TCR alpha chains were then cloned into pTa cassette vector in 
Xmal and Not1 sites, while the TCR beta chains were cloned into pTb cassette 
  
vector in Xhol and SacII sites, according to Kouskoff et al (Kouskoff et al., 1995). 
The ampicillin resistance gene was cut out with Sal I in pTa vectors and Kpn I in 
pTb vector before DNA injection. The TG6 transgenic mice were generated on 
the B6 background in the Cancer Research Laboratory Gene-Targeting Facility 
at UC Berkeley under standard procedures. The TR5 transgenic mice were 
generated on the B6 background in UC Davis Mouse Biology Program under 
standard procedures.  Founders were identified by flow cytometry and PCR 
genotyping of tail genomic DNA using primers mentioned above. The TG6 and 
TR5 mice used in all experiments were bred with B6.C mice to generate F1 (H-
2bxd) background. 
 
Flow cytometry 
All antibodies were from eBioscience (San Diego, CA), Biolegend (San Diego, 
CA) or Tonbo Biosciences (San Diego, CA), except for FITC-labeled anti-mouse 
T-bet antibody (Santa Cruz Biotech. Inc., Santa Cruz, CA). The GRA6:Ld, 
GRA4:Ld, and ROP5:Db tetramers were made by conjugating the biotin-labeled 
monomers (NIH tetramer facility, Atlanta, GA) with PE-labeled or APC-labeled 
streptavidin (Prozyme, Hayward, CA) according to protocols from the NIH 
tetramer facility. Brain samples were perfused and digested by collagenase 
before leukocytes isolation by 70%:30% percoll gradient (GE Heathcare, 
Pittsburgh, PA) (Grover et al., 2014). In some experiments, 3µg of FITC-labeled 
anti-CD45.1 (A20) antibody was injected intravenously into chronically infected 
mice 2 minutes before sacrifice and organ harvest (Anderson et al., 2014). In all 
experiments, cell suspension from the brain, lymph nodes and the spleens was 
incubated with tetramers and surface antibodies against mouse CD8 (53-6.7), 
B220 (RA3-6B2), CD27 (LG.7F9), CD44 (IM7), CD45.1 (A20), CD49d (R1-2), 
CD62L (MEL-14), CD122 (TM-E1), CD127 (A7R34), CXCR3 (CXCR3-173), PD-1 
(RMP1-30) and/or KLRG1 (2F1) for 1 hour at 4oC. For EdU labeling experiments, 
previously infected mice were injected intraperitoneally with 2mg EdU (5-ethynyl-
¶-deoxyuridine) for 14 hours before sacrifice. Cell suspensions were then 
stained with APC-labeled tetramers and other surface markers before EdU 
detection procedure during the Click-iT EdU Alexa-Fluor 488 Flow Cytometry Kit 
,QYLWURJHQ &DUOVEDG &$ DFFRUGLQJ WR PDQXIDFWXUHU¶V LQVWUXFWLRQ For all 
intracellular staining, samples stained with surface antibodies were fixed with 
Cytofix/Cytoperm kit (BD Pharmingen, San Diego, CA) or Transcription Factor 
Staining Buffer Set (eBioscience), followed by antibodies staining of intracellular 
TNFĮ (A20)IFNȖ(XMG1.2)T-bet (4B10), Eomes (Dan11mag), Ki67 (SolA15) 
and Bcl2 (10C4). All flow cytometry data were acquired by BD LSRFortessa 
analyzers (BD Biosciences) and were analyzed with FlowJo software (Tree Star, 
Ashland, OR). Fluorescent AccuCheck counting beads (Invitrogen) were used to 
calculate total numbers of live lymphocytes from all samples.  
 
ex vivo cytokine production assay 
Splenocytes from mice 60-140 days post infection were cultured with GRA6 
peptide or GRA4 and ROP5 peptide (Peptide2.0 Inc., Chantilly, VA) in media for 
4 hours with the presence of protein secretion block (eBioscience). Cells were 
  
then harvested for surface and intracellular antibody staining before flow 
cytometry analysis. 
 
GRA6 and ROP5 antigen presentation detection in vivo 
To provide a sensitive method to detect ongoing antigen presentation, we 
adopted a detection method in Turner et al (Turner et al., 2007). In brief, we 
harvested from lymph nodes (LNs) and spleen of CD45.2+ TG6 or TR5 mice 
H2bxd background, labeled with the cell proliferation dye eFluor 450 (eBioscience, 
San Diego, CA), transferred cells containing 105 TG6 or TR5 cells into previously 
CD45.1+ infected mice, and examined proliferation dye dilution 3 days later as a 
measure of GRA6 or ROP5 antigen presentation. Relative antigen levels are 
expressed as the % of donor TG6 or TR5 cells that have diluted proliferation dye 
(proliferation dyelow) 3 days after transfer. 
 
Adoptive transfer 
To expand TG6 cells in vivo, cells were harvested from lymph nodes (LNs) and 
spleen of CD45.2+ TG6 mice on H2bxd background and transferred into CD45.1+ 
naïve F1 recipients at 10,000-100,000 CD8+ TG6 cells/mouse one day before 
infection. For FACS sorting, pooled LNs and spleen cells from multiple recipients 
day 21 post infection were subjected to CD4+ T cell and B cell depletion by PE-
labeled anti-CD4 and anti-B220 antibodies and anti-PE magnetic beads (Miltenyi 
%LRWHF,QF6DQ'LHJR&$DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQ, followed 
by eFluor450 proliferation dye labeling. CXCR3+KLRG1-, CXCR3+KLRG1+, and 
CXCR3-KLRG1+ CD8+ TG6 cells were then sorted at   SXULW\ E\ D %'
influx cell sorter (BD Biosciences). Each sorted subset was then transferred to 
naïve or >day 21 post-infected secondary recipients at 105 cells/mouse. Donor 
TG6 cells were harvested between day 2 to day 21 post transfer for flow 
cytometry analysis. In some experiments, sorted TG6 cells were transferred to 
F1 rag-/- mice that were infected 1 day before transfer. Donor cells were 
harvested 8 days after transfer for flow cytometry analysis.  
 
In vitro cytotoxicity assay 
Sorted subsets of CXCR3+KLRG1-, CXCR3+KLRG1+, and CXCR3-KLRG1+ 
CD8+ TG6 cell subsets were obtained from infected mice as described above for 
adoptive transfer. Each subset was cultured with GRA6-peptide-pulsed and PBS-
pulsed splenocytes from congenically marked naïve F1 mice at 1:5:5 ratio. The 
GRA6-peptide-pulsed and PBS-pulsed splenocytes were distinguished by 
different intensity of CFSE labeling (5-(and-6)-Carboxyfluorescein Diacetate, 
Succinimidyl Ester, Invitrogen). Cytotoxicity was assessed by the loss of the 
GRA6-peptide-pulsed splenocytes relative to the PBS-pulsed control after 18 
hours of culture.  
 
In vivo cytotoxicity assay 
Splenocytes from F1 naïve mice were labeled with cell proliferation dye eFluor 
450 at four different levels of intensity. Each labeled population was then pulsed 
with either 1PM of GRA6, GRA4, ROP5-pepitdes (Peptide2.0 Inc.) or PBS for 1 
  
hour at 37oC. Pulsed cells were then washed twice and mixed at 1:1:1:1 ratio 
with 106 cells from each population. Cell mixture was injected intravenously into 
chronically infected mice and harvested 18 hours later.  
 
Mathematical modeling and Bayesian statistical analysis 
To construct the mathematical models for Figure 7, we made the following 
assumptions: 1a) Model 1 follows the linear order: Tmem (CXCR3+KLRG1-, called 
x1) Î Teff (CXCR3-KLRG1+, called x3); 1b) Model 2 follows the linear order: 
Tmem (CXCR3+KLRG1-, called x1) Î Tint (CXCR3+KLRG1+, called x2) Î Teff 
(CXCR3-KLRG1+, called x3); 2) Teff do not proliferate or further differentiate, and 
eventually die (death rate, P3). 3) Populations x1 and x2 are characterized by an 
intrinsic carrying capacity of the population, related to the resources available, 
designated N1 and N2, respectively. 4) For the sake of simplicity, death rates for 
populations x1 and x2 in the presence of antigen are assumed to be zero.  
However, we note that if substantial death does occur in these populations, this 
would be reflected in lower values for O1 and O2, and would not affect our overall 
conclusions. 
 
The equations for the mathematical models that describes the populations are:  
 
Model 1:  
  
(i)  
 
(ii) 
 
 
Model 2: 
 
 
(iii) ,   
  
 (iv) ,  
 
 (v) . 
 
The steady state of interest for the populations described above can be 
described by the following equations: 
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 (iv) ,  
  
(v)
   
 
Model 2: 
 
 (vi) ,  
 
(vii) ,
 
 
 
(viii) . 
 
We then determined a set of control parameters for the model (Table S1A). For 
the death rate of Teff (P3) we used 0.027 cells/day, based on the half-life of the 
population upon transfer into infected mice:  (Figure 5B and 5D). We 
used the EdU incorporation data (Figure 4A) to estimate O1 (self-renewal rate) 
andO2 (amplification rate).  (6% EdU labeling of the Tmem population x 24/14 
hours = 0.1 cells/day for O1 and 29% labeled x 24/14 hours = 0.5 cells/day for 
O2). We set [1 slightly lower than O1, and [2 slightly lower than O2, to provide for 
stable x1 and x2 populations over time. We calculated the carrying capacities N1 
and N2, based on the steady state equations (vi-viiii), the control parameters forO 
and [ and the mean number of x1 and x2 cells from day >40 infected mice from 
Figure 3. Figure 7C and 7D were generated in Mathematica (Wolfram, 
Champagne, IL) as a function of O1 and [1 (Figure 7C) or O2 and [ 2 (Figure 7D). 
Figure 7E was generated in Python (PSF, Beaverton, OR).  
 
To obtain a measure of the plausibility of the model and the control parameters, 
we performed a Bayesian statistical calibration of the model using the available 
data (steady state spleen T cell numbers and cell transfer data in Figure 3 and 
Figure 5). For the prior distributions, we used a combination of independent 
uniform and normal distributions that covered a wide range of possible parameter 
values. 
 
To set the likelihood structure and the level of approximation, we used the 
following Approximate Bayesian Computation (ABC) technique (Wilkinson, 
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2013): 1) Randomly draw from the prior distributions for the parameters; 2) Use 
the chosen parameter set to simulate data from the model so we have a model 
prediction for every observed data point; 3) Compare the simulated data with the 
observed data, and retain the set of parameters if they are similar enough; 4) 
Repeat steps 1 to 3 until the number of retained parameter sets is large. 
 
To compare the observed and simulated datasets, we used the following 
distance measure:  
 
 (ix) Distance (Data, Simulated Data) = Data - Simulated Data( )
2
Data2Data
å
 
 
 
which is a Euclidean distance that has been scaled by the magnitude of the 
observed data. We say that the observed and simulated datasets are similar 
enough if this distance is less than 30.  The resulting median values and 
probability functions show that the control parameters fall well within the 95% 
probability limits (Table S1B). Analysis was performed in Matlab (Mathworks, 
Natick, MA).  
 
Code Availability 
The mathematical equations for the number of cells of population x3 at steady 
state (Figure 7C and 7D), as a function of (model 1) O1 and [1 and of (model 2) 
O2 and [2 are provided as a Mathematica code in Supplementary File. The 
mathematical model to obtain the time course for the dynamics of the three 
populations (model 2 and Figure 7E) is provided as a numerical Python code in 
Supplementary File. Source code used for Bayesian statistical analysis is 
available upon request. 
 
Additional Statistical Analysis for Experimental Data 
All p-values were calculated using the two-tailed, unpaired 6WXGHQW¶V W WHVW RU
one-way analysis of variance with 7XNH\¶V post-test according to instructions in 
Prism (GraphPad, La Jolla, CA). A p-value < 0.05 was considered to be 
statistically significant. All data met the assumptions of the test (i.e. Gaussian 
distribution and similar variances between groups of data being compared). 
Sample size in all experiments was consistent with previous experience and 
similar studies. No samples or animals were excluded from the analysis. The 
investigators were not blinded to group assessment. 
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FIGURE LEGENDS 
 
Figure 1: CD8+ GRA6:Ld-specific T cell response to T.gondii in genetically 
resistant mice exhibits immunodominance, lack of a contraction phase, 
and a persistent polyfunctional effector response. (A) Kinetics of parasite 
burden in F1 H2bxd mice after oral infection with Pru strain parasites expressing 
RFP. Parasite loads in the mesenteric lymph node (MLN, filled circles) and in the 
spleen (open circles) are shown as numbers of RFP+ infected cells. Parasite 
loads in the brain were determined by semi-quantitative PCR. Each time point is 
displayed as number of parasite genomes per 1µg of brain genomic DNA (red 
triangles). (B) Representative flow cytometry plots showing GRA4:Ld-, ROP5:Db-, 
or GRA6:Ld-tetramer expression on gated CD8+ T cells from the spleens of F1 
mice day 21 after infection.  Numbers represent the percent of tetramer+ cells out 
of total splenic CD8+ T cells. (C) Number of GRA4:Ld- (black circles), ROP5:Db- 
  
(blue circles), or GRA6:Ld-(red circles)-tetramer-specific CD8+ T cells in the 
spleens (top) and the brains (bottom) of infected F1 mice at the indicated time 
points. (D) In vivo cytotoxicity of anti-T. gondii CD8+ T cells. Representative 
histograms showing the percent of each of each target cell populations pre-
transfer, or 18 hours after transfer into day 90 chronically infected mice. Target 
cells were individually pulsed with 1PM of indicated peptides and labeled with a 
different concentration of fluorescent dye, then mixed at 1:1:1:1 ratio just prior to 
injection into mice. Values are the percent of each donor population before and 
after transfer. (E) Left panel shows representative flow cytometry plots showing 
IFNȖ and TNFĮ production of splenic CD8+ T cells from day 140 chronically 
infected F1 mice after ex vivo stimulation with indicated peptides for 4 hours. 
Values are the percent of IFNȖ positive cells out of total CD8+ T cells. Right 
panel shows the percentage of TNFĮ producing cells amongst IFNȖ+CD8+ T 
cells following stimulation with a serial dilution of GRA6 (red) or a mixture of 
GRA4 and ROP5 peptides (black). (F) Kinetics of surface KLRG1, CD62L, and 
PD-1 expression.  Values are the percent positive cells out of each of the splenic 
GRA4:Ld-(black circles), ROP5:Db- (blue circles), and GRA6:Ld- (red circles) 
tetramer+ CD8+ T cell population from mice between day 0 and day 200 post 
infection. Graph in (A-C, F) are summary of 3-5 independent experiments with 
total N equal to 4-10 mice at each time point. (D, E) are representative of 3 
independent experiments with total N=5 mice 2-4 months post infection. Graphs 
in (A, C and F) display mean sS.E.M. 
 
  
Figure 2. Kinetics of antigen presentation in vivo correlates with GRA6:Ld-
specific T cell proliferation during the chronic phase. (A) Strategy for 
quantification of in vivo GRA6 antigen levels in infected mice. (See also 
Experimental Procedures). (B) Representative flow cytometry plots of donor TG6 
T cells recovered 3 days after injection into day 140 post infection mice. Control 
infected mice were infected with CEP strain parasites, which express an allelic 
form of GRA6 that lacks the relevant T cell epitope. (C) Compiled data showing 
GRA6 antigen presentation in vivo as measured by the proliferation of TG6 T 
cells recovered 3 days after transfer into mice that had been previously infected 
for the indicated times (red circles).  Percentage of Ki67+ cells out of total 
endogenous splenic GRA6:Ld-tetramer+ CD8+ T cells in orally infected mice 
(black circles) are shown for comparison. (D) Representative flow cytometry plots 
showing Ki67 expression and 14-hour in vivo EdU labeling by gated splenic 
GRA6:Ld-specific CD8+ splenic T cells at day 15 or day 148 after infection. 
Panels in (B and D) are representative of 3 independent experiments with total 
N=5-6 mice per group. Graph in (C) is summary of 3 independent experiments 
with total N equal to 4-5 mice at each time point. Values are percent of cells in 
the indicated gates or quadrants. 
 
Figure 3: GRA6:Ld-specific T cell immunodominance correlates with the 
predominance and stability of the CXCR3+KLRG1+ population.  (A) 
Representative flow cytometry plots showing CXCR3 vs. KLRG-1 expression of 
splenic GRA6:Ld- and GRA4:Ld/ROP5:Db-tetramer+ CD8+ T cells isolated at the 
  
indicated times after infection. Naïve CD44low CD8+ T cells are shown in grey for 
reference. (B) Total numbers of splenic CXCR3+KLRG1-, CXCR3+KLRG1+ and 
CXCR3-KLRG1+ cells within the GRA6:Ld- (open circles) or GRA4:Ld/ROP5:Db-
(filled circles) tetramer+ CD8+ T cells over time after infection. The dashed line 
indicates the detection limit of this assay at 103 cell/spleen. (C) Kinetic of total 
splenic donor TG6 cells (left) and number of splenic donor TG6 CXCR3+KLRG1-
, CXCR3+KLRG1+ and CXCR3-KLRG1+ cells (right) after infection. Panels in (A) 
are representative of 3-6 independent experiments with total N=5-8 mice at each 
time point. Graphs in (B and C) are summary of 3-5 independent experiments 
with total N equal to 3-8 mice at each time point, except in (B), day 140 post 
infection (2 independent experiment with total N equal to 2 mice). Graphs in (B 
and C) display meansS.E.M. 
 
Figure 4: The CXCR3+KLRG1+ subset is enriched with proliferating cells 
and has characteristics of both memory and effector cells. (A) Compiled 
scattered plots showing the percentages of Ki67+ (left), CD71+CD98+ (middle) 
and EdU+ (right) cells in each of the splenic GRA6:Ld-specific CXCR3/KLRG-1 
subsets 60 days after infection. (B) Compiled scattered plot showing the mean 
fluorescent intensity (MFI) of Bcl-2 staining in each of the splenic GRA6:Ld-
WHWUDPHU&;&5./5*VXEVHWVDWGD\VDIWHULQIHFWLRQ'DWDSRLQWVIURP
the same animal are indicated by connecting lines. Each symbol indicates value 
from individual recipients. (C) Representative histograms showing expression of 
memory/effector T cell markers CD127, CD122, CD62L, CCR7, CD27, CD43, 
  
Blimp-1, Eomes, and T-bet in each of the splenic GRA6:Ld-specific 
CXCR3/KLRG-1 subsets 60 days after infection. All panels are summary of 3-6 
independent experiments per group. *P < 0.05, **P < 0.01, and ***P < 0.001 
(one-ZD\$129$ZLWK7XNH\¶VSRVWWHVW 
 
Figure 5: Lineage relationship and antigen dependence of the 
CXCR3/KLRG1 subsets. (A) Representative flow cytometry plots showing the 
CXCR3/KLRG1 phenotype and proliferation dye profile of each of the sorted 
GRQRU7*VXEVHWVGD\VRUGD\VDIWHUWUDQVIHULQWRGD\LQIHFWHG
recipients. (B) Fold change in the number of the indicated CXCR3/KLRG1 donor-
derived subsets between 2-21 days after transfer into infected recipients. Each 
filled circle represents the value from an individual recipient at day 21 normalized 
to the mean value of day 2 post transfer for that subset from all experiments. 
Numbers inside the graphs indicate the mean fold change for each subset 
between day 2 and day 21. (C) Representative flow cytometry plots showing the 
CXCR3/KLRG1 phenotype and proliferation dye profile of each of the donor TG6 
subsets 2 days or 21 days after transfer of the indicated sorted subsets into 
naïve F1 recipient mice. (D) Fold change in the number of the indicated 
CXCR3/KLRG1 donor-derived subsets between 2-21 days after transfer into 
naive recipients. Each filled circle represents the value from an individual 
recipient at day 21 normalized to the mean value of day 2 post transfer for that 
subset from all experiments. Numbers inside the graphs indicate the mean fold 
change for each subset between day 2 and day 21. *P < 0.05, **P < 0.01, and 
  
***P < 0.001 (one-ZD\$129$ZLWK7XNH\¶VSRVWWHVW$OOSDQHOVDUH
representative of 3-4 independent experiments. Total N of each panel is 
indicated in the corresponding scattered plots. (B, D) Half-lives of each subset 
(t1/2) were calculated by: , N = donor TG6 cell 
number recovered at day 2 or day 21 post transfer. 
 
Figure 6: Persistent antigen presentation prevents T cell contraction by 
sustaining the Tint population. (A-B) Kinetics of splenic GRA6 antigen 
presentation in vivo, as measured by proliferation of naïve TG6 T cells 3 days 
after transfer into infected mice (see also Figure 2A) (A), and splenic GRA6:Ld-
tetramer+ CD8+ T cell number (B) in mice infected with either 105 live (filled 
circles) or 106 irradiated (open circles) T. gondii intraperitoneally. (C) 
Representative histograms showing Ki67 expression of each of the splenic 
GRA6:Ld-specific CXCR3/KLRG1 subsets in mice infected with 105 live or 106 
irradiated T. gondii intraperitoneally at 12 or 21 days post infection. (D) 
Representative flow cytometry plots showing CXCR3/KLRG1 profiles of splenic 
GRA6:Ld-tetramer+ CD8+ T cells from mice infected with 105 live or 106 
irradiated T. gondii intraperitoneally at 7, 12, or 21 days post infection. (E) (left) 
Kinetics of each of the splenic GRA6:Ld-tetramer+ CD8+ CXCR3/KLRG1 subsets 
from mice infected with 105 live (filled circles) or 106 irradiated (open circles) T. 
gondii intraperitoneally. (right) Histogram indicated the fold reduction of cell 
numbers in each T cell group between day 12 and 21 in mice infected with 106 
irradiated T. gondii. (F) Kinetics of splenic ROP5 antigen presentation in vivo (red 
t1/2 =19days * ln 2( ) / ln Nday2 / Nday21( )
  
circles), as measured by proliferation of naïve ROP5:Db T cells from TR5 TCR 
transgenic mice 3 days after transfer into orally infected mice (see also Figure 
2A.)  Numbers of splenic GRA4:Ld/ROP5:Db-specific CXCR3+KLRG1+ cells 
(black circle) from Figure 3B are shown for comparison.  Right panel shows 
comparable data for splenic GRA6 antigen presentation in vivo and numbers of 
splenic GRA6:Ld-specific CXCR3+KLRG1+ T cells.  GRA6 antigen presentation 
data is also displayed in Figure 2C, and is included here for comparison.  Graph 
in (A) is summary of 2 independent experiments with total N equal to 3-4 mice at 
each time point. Each symbol indicates value from individual recipients. Graph in 
(B), *P = 0.043 and **P = 0.003 (unpaired, two-tailed student t-test); Graph in (E), 
*P = 0.02 (one-ZD\$129$ZLWK7XNH\¶V post test). Graphs in (B and E) are 
summary of 3-4 independent experiments with total N equal to 4-7 mice at each 
time point. Panels in (C, D, and F) are representative of 3 independent 
experiments with total N=3-5 mice at each time point. Graphs in (A, B, E and F) 
display meansS.E.M. 
 
Figure 7: Mathematical modeling illustrates the role of the amplifying Tint 
subset in maintaining a robust Teff response. Mathematical models describing 
the population dynamics of the GRA6:Ld response with (A) or without (B) the Tint 
susbet.  See also Experimental Procedures for details. (C) Graph showing 
dependence of Teff cell numbers at steady state on the values of Tmem self-
renewal rate O1 and differentiation rate [1, according to model 1 in panel (A). 
The remaining parameters were fixed at the control values (see also Table S1A). 
  
(D) Graph showing dependence of Teff cell numbers at steady state on the values 
of Tint amplification rate O2 and differentiation rate [2, according to model 2 in 
panel (B). The remaining parameters were fixed at the control values (see also 
Table S1A). The red dashed line indicates the experimental value for number of 
Teff found in spleens of chronically infected mice.  (E) Changes in number of 
Tmem, Tint, and Teff populations as a function of time starting with 105 Tmem using 
the model 2 in panel (B) and control parameters (see also Table S1A). 
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Figure S1. Related to Figure 1. Phenotype of brain resident GRA6:Ld-
specific T cells in chronically infected mice. (A) Representative flow 
cytometry plots showing the percentage of GRA6:Ld (Left) or GRA4:Ld+ROP5:Db 
(Right) -specific T cells out of total CD8+ T cells in the brain of day 56 orally 
infected mice. (B) Representative flow cytometry plots showing surface 
expression of CXCR3, KLRG1, CD69 and CD103 on brain parenchyma (CD45.1-
) and vascular ±associated (CD45.1+) GRA6:Ld-specific T cells from day 100 
orally infected CD45.1+ mice. Mice were injected i.v. with FITC-conjugated 
CD45.1 antibodies just prior to sacrifice to label blood-exposed lymphocytes. 
 
Figure S2. Related to Figure 3. Characterization of the GRA6:Ld-specific 
TCR transgenic (TG6) mice. (A) TCR alpha and beta chain information of the 
GRA6:Ld-specific TCR used to create the TG6 transgenic mice. (B) 
Representative flow cytometry plots showing the TCR expression and phenotype 
of splenocytes of the TG6 mice. Panel (B) is representative of 5 independent 
experiments with total N=8 mice per group. Values are percent of cells in the 
indicated gates or quadrants. 
 
Figure S3. Related to Figure 3 and Figure 4. CXCR3 and KLRG1, but not 
other commonly used memory/effector markers, identify a proliferative 
subset within the antigen-experienced GRA6:Ld-specific T cells during 
chronic infection.  (A) Representative histograms showing CCR7 and CD62L 
expression on GRA6:Ld-specific CD8+ splenic T cells (solid line) and total 
5HYLVHG6XSSOHPHQWDO)LJXUH/HJHQGV &OLFNKHUHWRGRZQORDG6XSSOHPHQWDO7H[W	)LJXUHV6XSSO)LJXUH/HJHQGVKFGRF[
CD44low CD8+ T cells (shaded) in orally infected mice 60 days post infection. (B) 
Representative flow cytometry plots showing the frequencies of subsets gated 
based on CD127/KLRG1 expression and CXCR3/KLRG1 expression in Ki67high 
or Ki67neg GRA6:Ld-specific CD8+ splenic T cells in orally infected mice 40 days 
post infection. (C) Representative histograms comparing the Ki67 expression 
between each of CD127/KLRG1 (dotted line) and CXCR3/KLRG1 (solid line) 
subsets in GRA6:Ld-specific CD8+ splenic T cells in orally infected mice 40 days 
post infection. (D) Representative flow cytometry plots showing phenotypes of 
TG6 T cells after infection. Twenty-thousand naive CD45.2+ TG6 T cells were 
transferred into naïve CD45.1+ F1 mice one day before infection. CXCR3 and 
KLRG1 expression of donor TG6 cells were examined 28 days and 120 days 
after infection. (E) Representative flow cytometry plots showing the post sort 
purity of individual TG6 CXCR3/KLRG1 subsets after 28 days of infection. (F) in 
vitro cytotoxicity of TG6 T cell subsets. Each subset was cultured with GRA6-
peptide pulsed splenocytes at 1:5:5 ratio. Splenocytes were harvested at day 1 
post culture. Killing capacity indicates the percent loss of the GRA6-pulsed 
splenocytes relative to unlabeled target cell control. Panels in (A, B,and C) are 
representative of 3 independent experiments with total N=3-6 mice per group.  
Panels in (D, E and F) are representative of 10, 8 and 3 independent 
experiments respectively. Values are percent of cells in the indicated gates or 
quadrants. Graph in (F) display mean sS.E.M. Nonlinear regression with least-
square fitting method was used to determine best-fit curves. Values are percent 
of cells in the indicated gates or quadrants. 
 Figure S4. Related to Figure 5. Lineage tracing of the TG6 CXCR3/KLRG1 
subsets. (A) Experimental design. (B) Representative flow cytometry plots 
showing the CXCR3/KLRG1 phenotype of each of the sorted donor TG6 subsets 
8 days after transfer into F1 rag-/- recipients infected 1 day before transfer (left). 
Total donor cell number recovered from each recipient is shown in the histogram 
(right). Horizontal line indicates the number of donor cells transferred. Each 
symbol indicates value from individual recipients. Panels are summary of 2-3 
independent experiments per group. Total N = 3 or 6 recipients per group.  
 
Figure S5. Related to Figure 6. Characterization of the ROP5:Db-specific 
TCR transgenic (TR5) mice. (A) TCR alpha and beta chain information of the 
ROP5:Db-specific TCR used to create the TR5 transgenic mice. (B) 
Representative flow cytometry plots showing the TCR expression and phenotype 
of splenocytes of the TR5 mice. Panel (B) is representative of 3 independent 
experiments with total N=5 mice per group. Values are percent of cells in the 
indicated gates or quadrants. 
 
Figure S6. Related to Figure 7. Schematic of the cellular mechanism that 
maintains the GRA6:Ld T cell response in persistently infected, resistant 
mice.  (A) After the initial control of acute infection, the levels of in vivo 
presentation of GRA6 antigen decline relatively slowly.  (B) Persistent antigen 
presentation during chronic infection supports low-level proliferation of Tmem cells 
and their differentiation into rapidly proliferating Tint cells.  Antigen presentation 
supports the proliferation of Tint cells and drives their differentiation into Teff cells.  
Production of new Teff via the Tint population occurs at a rate that balances their 
death rate, so that the steady state levels of Teff remain high throughout infection.  
(C) Antigen presentation drops more sharply for subdominant antigens, or when 
parasites cannot replicate.  (D) In the absence of antigen presentation, Tmem cells 
are relatively long-lived, but no longer divide or differentiate.  Tint cells die rapidly 
and cease to differentiate into Teff cells in the absence of antigen presentation, 
leading to the contraction of the T cell response. The estimated in vivo half-life 
(t1/2 ) for each non-replicating population is indicated. 
Table S1. Related to Figure 7. 
 
A. Control parameters for Figure 7C, D and E.   
 
 
B. Preliminary Bayesian Study 
 
 
Table S1. Parameters for GRA6:Ld-specific T cell differentiation modeling 
during chronic phase. (A) Control parameters used to construct Figure 7C, 7D 
and 7E. Numbers were estimated from experimental data (see also Experimental 
Procedures). (B) Posterior range and median of each parameters calculated by 
Approximate Bayesian Computation (ABC) analysis from the experimental data 
to test the plausibility of the control parameters in (A).  
 
Parameters P       x1 
Control 
Values 
0.027 0.1 0.5 0.09 0.4 1.05x106 4.60x105 105 
units /days /days /days /days cells cells cells cells 
Parameters P       
Posterior 
median 
0.05 0.4 0.46 1.97 2.28 4.72x106 5.00x106 
Posterior 2.5th 0.01 0.02 0.02 0.21 0.31 1.96x105 2.04x105 
Posterior 
97.5th 
0.09 1.66 1.81 3.91 3.92 9.70x106 9.76x106 
units /days /days /days /days cells cells cells 
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